Newsroom

دالاس--(BUSINESS WIRE)--أصدرت اليوم شركة Mary Kay Inc.‎، الرائدة عالميًا في مجال التجميل والملتزمة بمبادئ الاستدامة وتمكين المرأة، تقرير الاستدامة لعام 2026، الذي يستعرض التقدم المحرز نحو تحقيق أهدافها لعام 2030، ويحتفي بأحدث إنجازاتها لعام 2025 التي تواصل دفع عجلة التغيير الإيجابي على مستوى العالم.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20260730008269/ar/يسلط تقرير الاستدامة السنوي لعام 2026 الصادر عن Mary Kay الضوء...

HANOVER, Pa.--(BUSINESS WIRE)--Utz Quality Foods, LLC (Utz), a subsidiary of Utz Brands, Inc. and the maker of the beloved Utz® Cheese Balls, was an official sponsor of Beer Bowl 2026, the annual charity event hosted by Jason and Kylie Kelce in Sea Isle City, N.J. benefiting the Eagles Autism Foundation. The event featured Utz’s iconic Cheese Balls in the Utz x Garage Beer "Million Cheese Ball Challenge™," along with fan activations, celebrity appearances and a shared mission of raising funds f...

LAS VEGAS--(BUSINESS WIRE)--GMO Internet Group sends elite white-hat hackers to DEF CON 34 CTF (Las Vegas, Aug 6–9), chasing a 4th Cloud Village title and first Finals win....

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE KEY INFORMATION Name of person dealing (Note 1)   Fund(s) for whom Sand Grove Capital Management LLP is the Investment Manager Company dealt in   Irish Continental Group Plc Class of relevant security to which the dealings being disclosed relate (Note 2)   €0.065 ordinary s...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mu...

LONDON--(BUSINESS WIRE)--    FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)   Fund(s) for whom Sand Grove Capital Management LLP is the Investment Manager Company dealt in   Permanent TSB Group Holdings plc Class of relevant security to which the dealings being disclosed relate (Note 2)   €0.01 o...

NEW YORK--(BUSINESS WIRE)--KBRA is providing an update on Series 2024-1 and Series 2025-1 (collectively, the Notes) from ExteNet Issuer, LLC (the Issuer), the issuer of a communications infrastructure securitization. According to a recent notice posted by Wilmington Trust, N.A (the Indenture Trustee), the following events of default have occurred: The Issuer failed to pay accrued interest due on the Notes on the July 27, 2026 payment date. Liens granted under the transaction documents with resp...

ROTKREUZ, Suisse--(BUSINESS WIRE)--Polpharma Biologics International AG annonce aujourd’hui que la Food and Drug Administration (FDA) américaine et l’Agence européenne des médicaments (EMA) ont accepté d’examiner respectivement la demande d’autorisation de mise sur le marché de produits biologiques (BLA) et la demande d’autorisation de mise sur le marché (MAA) pour le PB016, un candidat biosimilaire du vedolizumab destiné à remplacer le produit de référence d’Entyvio®* de Takeda (vedolizumab),...

ROTKREUZ, Svizzera--(BUSINESS WIRE)--Polpharma Biologics International AG oggi ha reso noto che la Food and Drug Administration (FDA) degli Stati Uniti e l'Agenzia europea per i medicinali (EMA) hanno accettato la richiesta di revisione relativa rispettivamente alla domanda di licenza per farmaci biologici (BLA) e alla domanda di autorizzazione alla commercializzazione (MAA) per PB016, un candidato biosimilare di vedolizumab rispetto a Entyvio®* (vedolizumab), il prodotto di riferimento di Take...

ROTKREUZ, Schweiz--(BUSINESS WIRE)--Die Polpharma Biologics International AG gibt heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) und die Europäische Arzneimittelagentur (EMA) den Antrag auf Zulassung eines Biologikums (Biologics License Application, BLA) bzw. den Antrag auf Marktzulassung (Marketing Authorisation Application, MAA) für PB016 zur Prüfung angenommen haben. Dabei handelt es sich um einen geplanten Vedolizumab-Biosimilar-Kandidaten für Takeda's Referenzp...